Archiv
Archiv anzeigen:
bis


An Oral Gonadotropin-Releasing Hormone Antagonist for Advanced Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Shore ND et al. N Engl J Med 2020 May 29

Relugolix was superior to the injectable luteinizing hormone–releasing hormone agonist leuprolide in providing sustained suppression of testosterone.


Chemotherapy for Breast Cancer Patients with High Recurrence Scores

William J. Gradishar, MD reviewing Ma SJ et al. JAMA Netw Open 2020 May 1

Adjuvant chemotherapy was associated with improved overall survival for patients with recurrence scores of 26 or higher.


Immunotherapy plus Chemotherapy for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Galsky MD et al. Lancet 2020 May 16, Szabados B and Powles T. Lancet 2020 May 16

Adding atezolizumab to platinum-based chemotherapy significantly prolonged progression-free survival.


Selumetinib for Children with Inoperable Plexiform Neurofibromas

Roy E. Strowd, MD reviewing Gross AM et al. N Engl J Med 2020 Apr 9

Most patients had durable response and improved clinical benefit in a phase II study.


Risk for Thrombosis in Patients with Sickle Cell Disease

Brady L. Stein, MD, MHS reviewing Srisuwananukorn A et al. Blood Adv 2020 May 12

Thrombosis is prevalent in sickle cell patients, especially following hospital discharge and in the presence of vascular access, and is potentially influenced by thrombomodulin gene mutations.


Bevacizumab plus Atezolizumab for Advanced Hepatocellular Cancer

David H. Ilson, MD, PhD reviewing Finn RS et al. N Engl J Med 2020 May 14

Survival was significantly prolonged with combination therapy versus conventional therapy with sorafenib.


Olaparib for Metastatic Castration-Resistant Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing de Bono J et al. N Engl J Med 2020 Apr 28

Progression-free survival was longer with olaparib than with abiraterone or enzalutamide in patients with BRCA1, BRCA2, or ATM alterations.


Aspirin Dosing for Essential Thrombocythemia

Brady L. Stein, MD, MHS reviewing Rocca B et al. Blood 2020 Apr 7

Increasing the frequency of low-dose aspirin dosing improved platelet inhibition.


NEJM Journal Watch Coverage of “Preprints”

Allan S. Brett, MD

Our approach to considering non–peer-reviewed studies during the COVID-19 pandemic


Pemigatinib for Advanced Cholangiocarcinoma

David H. Ilson, MD, PhD reviewing Abou-Alfa GK et al. Lancet Oncol 2020 Mar 20

Among previously treated patients with FGFR2 fusions or rearrangements, 36% achieved an objective response.


Archiv
Seite von 93